Icatibant Fresenius

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as an injectable solution for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with confirmed diagnosis. The medication works by rapidly counteracting bradykinin‑mediated swelling, providing relief within minutes of administration.

GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and specialty clinics worldwide, ensuring reliable cold‑chain logistics and regulatory compliance for this injectable therapy.

Icatibant Fresenius is used to manage hereditary angioedema, a disorder characterized by excessive bradykinin activity. - Hereditary angioedema attacks: reduces swelling and pain by blocking bradykinin B2 receptors. - Hereditary angioedema type I: provides rapid symptom relief during acute episodes. - Hereditary angioedema type II: alleviates airway and peripheral edema during attacks.

Icatibant Fresenius may be associated with several adverse reactions following subcutaneous administration. Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema around the injection area. - Nausea: transient feeling of queasiness. - Headache: mild headache occurring shortly after dosing. - Dizziness: temporary light‑headedness. Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis requiring immediate medical attention. - Angioedema of the throat: swelling that may compromise airway. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count observed in rare cases.

When prescribing Icatibant Fresenius, clinicians should consider several precautionary measures to ensure safe use. - Patient history: assess for known hypersensitivity to icatibant or its excipients. - Cardiovascular status: monitor patients with unstable blood pressure or cardiac disease. - Concomitant ACE inhibitors: evaluate risk of additive angioedema. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Renal or hepatic impairment: no dosage adjustment required but monitor clinical response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Fresenius can interact with other medicines, influencing its efficacy or safety. Major Interactions (Avoid): - ACE inhibitors: may increase risk of angioedema when combined with icatibant. - Angiotensin receptor blockers (ARBs): similar risk of enhanced bradykinin‑mediated swelling. Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may potentiate bradykinin effects. - Other B2 receptor antagonists: additive pharmacodynamic effects. - CYP450 substrates: icatibant is not a major CYP inhibitor, but monitor for unexpected changes.